Abstract: A turbine module comprises a turbine shaft, a rotor assembly secured to the shaft, a bearing assembly rotatably supporting the turbine shaft, and a bearing housing containing the bearing assembly. The bearing housing includes a gutter at least partially circumscribing the bearing assembly, and a drain disposed proximate a base of the gutter. The gutter includes a first sloped floor portion circumferentially adjacent to the drain.

Abstract: A turbine module comprises a turbine shaft, a rotor assembly secured to the shaft, a bearing assembly rotatably supporting the turbine shaft, and a bearing housing containing the bearing assembly. The bearing housing includes a gutter at least partially circumscribing the bearing assembly, and a drain disposed proximate a base of the gutter. The gutter includes a first sloped floor portion circumferentially adjacent to the drain.

Abstract: A turbine module comprises a turbine shaft, a rotor assembly secured to the shaft, a bearing assembly rotatably supporting the turbine shaft, a bearing housing containing the bearing assembly, and a bearing compartment containing the bearing housing. A bearing compartment wall has at least one integral fluid supply passage in fluid communication with the bearing housing. The at least one integral fluid passage extends generally longitudinally through the bearing compartment wall.

Abstract: The present invention relates to double-crosslinked collagen materials, methods for preparing double-crosslinked collagen materials, and methods of using double-crosslinked

Abstract: The present invention relates to recombinant gelatins and compositions thereof, and methods of producing and using the same.

Abstract: The present invention relates to recombinant gelatins and compositions thereof, and methods of producing and using the same.

Abstract: The present invention relates to recombinant gelatins and compositions thereof, and methods of producing and using the same.

Abstract: The present invention relates to vaccines comprising recombinant gelatin, to methods of producing and using such vaccines, and to vaccination kits.

Abstract: Methods are disclosed for simplified recombinant production of fibrillar collagens. DNAs encoding fibrillar collagen monomers lacking the N propeptide, the C propeptide, or both propeptides are introduced into recombinant host cells and expressed. Trimeric collagen is recovered from the recombinant host cells.

Abstract: New forms of ecarin, a procoagulant protein from Echis carinatus venom, are described, as are polynucleotides encoding the new proteins, methods for production of the new proteins, and methods for activation of prothrombin using the new proteins. The new ecarins comprise a serine at position 396 of the protein. The new proteins may be used for activation of prothrombin, and are particularly useful for the production of recombinant thrombin.

Abstract: Methods are disclosed for simplified recombinant production of fibrillar collagens. DNAs encoding fibrillar collagen monomers lacking the N propeptide, the C propeptide, or both propeptides are introduced into recombinant host cells and expressed. Trimeric collagen is recovered from the recombinant host cells.

Abstract: The present invention relates to a thermally compliant liner for a gas turbine engine. The liner includes an outer wall, an inner wall spaced radially inwardly from the outer wall leaving a duct therebetween. A plurality of stiffeners are disposed in the duct. The stiffeners include a flexible medial portion which accommodates differential rates of thermal growth between the outer and inner walls. The stiffeners also include radially extending portions which in conjunction with the medial portion, minimize buckling of the liner due to pressure differentials.

Abstract: The invention is directed to the use of a fusion partner that does not contain a leader sequence, as a means to increase the solubility and activity of recombinant polypeptides by facilitating the expression of fusion proteins, which are then transported out of the cytoplasm. The invention includes a nucleic acid encoding a fusion polypeptide comprising a mature interleukin-1-like polypeptide or a leader-deleted-translocating polypeptide, and a polypeptide of interest; as well as host cells comprising such nucleic acids, and fusion proteins so encoded. The invention also encompasses methods of using such nucleic acids to produce recombinant fusion polypeptides, mature polypeptides of interest, and purified compositions thereof.

Abstract: The invention is directed to the use of IL-1-like fusion polypeptides to increase the solubility and activity of recombinant polypeptides. The invention includes a nucleic acid encoding a fusion polypeptide comprising an interleukin-1-like polypeptide and a polypeptide of interest and the method of using such a nucleic acid to produce recombinant fusion polypeptides.

Abstract: A method of treating TGF-.beta. excess is disclosed. The treatment is parenteral, oral or topical administration of TGF-.beta. receptor fragment. Particularly effective is a soluble receptor fragment which resembles the extracellular portion of TGF-.beta. binding protein II.

Abstract: The invention is directed to the use of a fusion partner that does not contain a leader sequence, as a means to increase the solubility and activity of recombinant polypeptides by facilitating the expression of fusion proteins, which are then transported out of the cytoplasm. The invention includes a nucleic acid encoding a fusion polypeptide comprising a mature interleukin-1-like polypeptide or a leader-deleted-translocating polypeptide, and a polypeptide of interest; as well as host cells comprising such nucleic acids, and fusion proteins so encoded. The invention also encompasses methods of using such nucleic acids to produce recombinant fusion polypeptides, mature polypeptides of interest, and purified compositions thereof.

Abstract: The invention is directed to the use of IL-1-like fusion polypeptides to increase the solubility and activity of recombinant polypeptides. The invention includes a nucleic acid encoding a fusion polypeptide comprising an interleukin-1-like polypeptide and a polypeptide of interest and the method of using such a nucleic acid to produce recombinant fusion polypeptides.